-
Product Insights
NewNet Present Value Model: Celcuity Inc’s Gedatolisib
Empower your strategies with our Net Present Value Model: Celcuity Inc's Gedatolisib report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Scholar Rock Holding Corp’s Apitegromab
Empower your strategies with our Net Present Value Model: Scholar Rock Holding Corp's Apitegromab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DN-1508052 in Cervical Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DN-1508052 in Cervical Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DN-1508052 in Cervical Cancer Drug Details: DN-1508052 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Dabrafenib Mesylate in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dabrafenib Mesylate in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dabrafenib Mesylate in Bile Duct Cancer (Cholangiocarcinoma) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NA-0113 in Female Contraception
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NA-0113 in Female Contraception report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.NA-0113 in Female ContraceptionDrug Details:NA-0113 is under development for the treatment of female...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – APX-3330 in Hepatitis C
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - APX-3330 in Hepatitis C report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. APX-3330 in Hepatitis C Drug Details: APX-3330 is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Gedatolisib in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gedatolisib in Metastatic Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gedatolisib in Metastatic Breast Cancer Drug Details: Gedatolisib (PF-05212384, PKI-587) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gedatolisib in Small-Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gedatolisib in Small-Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Gedatolisib in Small-Cell Lung Cancer Drug Details:Gedatolisib (PF-05212384, PKI-587) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gedatolisib in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gedatolisib in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Gedatolisib in Human...